Emmy and Benedicte learned about research into neuroscience and how to use modern medical technology, such as CRISPR, when on work placement with researcher Marianne Fyhn and her colleagues at the University of Oslo. Photo: Monica Jenstad

Learning about the human brain

Oslo Cancer Cluster and Ullern Upper Secondary School arranged a work placement for students to learn about neuroscience at the University of Oslo.

Four biology students from Ullern Upper Secondary School spent two great days on work placement with some of the world’s best neuroscientists at the University of Oslo. In Marianne Fyhn’s research group, the students tried training rats and learned how research on rats can provide valuable knowledge about the human brain.

The Ullern students, Benedicte Berggrav, Lina Babusiaux, Maren Gjerstad Høgden and Emmy Hansteen, first had to dress in green laboratory clothes, hairnets and gloves. They also had to leave their phones and notepads behind, before enterring the animal laboratory where Marianne Fyhn and her colleagues work. Finally, they had to walk through an air lock that blew the last remnants of dust and pollution off them.

On the other side was the most sacred place for researchers: the newly refurbished animal laboratory. It is in the basement of Kristine Bonnevies Hus on the University of Oslo campus. We used to call it “Bio-bygget” (“the bio-building”) when I studied here during the ‘1990s.

 

Researcher Kristian Lensjø showed the four excited biology students into the most sacred place: the animal lab.

It is the second day of the students’ work placement with Marianne. The four biology students, who normally attend the second year of Ullern Upper Secondary School, have started to get used to their new, temporary jobs. They are standing in one of the laboratories and looking at master student Dejana Mitrovic as she is operating thin electrodes onto the brain of a sedated rat. PhD student Malin Benum Røe is standing behind Dejana, watching intently, giving guidance and a helping hand if needed.

“We do this so we can study the brain cells. We will also find out if we can guide the brain cells with weak electrical impulses. This is basic scientific research. In the long term, the knowledge can help to improve how a person with an amputated arm can control an artificial prosthetic arm,” Marianne explained.

“The knowledge can help to improve how a person with an amputated arm can control an artificial prosthetic arm.”

Dejana needs to be extremely precise when she connects the electrodes onto the rat’s brain. This is precision work and every micrometre makes a difference.

 

Training rats

The previous day, Maren, Benedicte, Lina and Emmy helped to train the rat on the operating table on a running course. Today, the Ullern students will train the other rats that haven’t had electrodes surgically connected to their brains yet.

“We will train the rats to walk in figures of eight, first in one direction and then the other”, the students explained to me.

We remain standing in the rat training room for a while, talk with Dejana and train some of the rats. Dejana tells me that the rats don’t have any names. After all, they are not pets, but they are cared for and looked after in all ways imaginable.

“It is very important that they are happy and don’t get stressed. Otherwise, they won’t perform the tasks we train them to do,” says Dejana. She and the other researchers know the animals well and know to look for any signs that may indicate that the rats aren’t feeling well.

“It is very important that they are happy and don’t get stressed.”

I ask the students how they feel about using rats for science.

“I think it is completely all right. The rats are doing well and can give us important information about the human brain. It is not okay when rats are used to test make-up and cosmetics, but it is a whole different matter when it concerns important medical research,” says Emmy and the other biology students from Ullern nod in agreement.

 

Understanding the brain

Marianne is the head of the CINPLA centre at the University of Oslo, where Maren, Benedicte, Lina and Emmy are on work placement for two days. Four other Ullern students, Henrik Andreas Elde, Nils William Ormestad Lie, Hans Christian Thagaard and Thale Gartland, are at the same time on a work placement with Mariannes research colleague, Professor of Physics Anders Malthe-Sørenssen. They are learning about methods in physics, mathematics and programming that help researchers to better understand the brain.

“CINPLA is an acronym for Centre for Integrative Neuroplasticity. We try to bring together experimental biology with calculative physics and mathematics to better understand information processing in the brain and the brain’s ability to change itself,” says Marianne.

Physics, mathematics and programming are therefore important parts of the researcher’s work when analysing what is happening in the rat’s brain.

If you think that research on rats’ brain cells sounds familiar, then you are probably right. Edvard and May-Britt Moser in Trondheim received the first Norwegian Nobel Prize in Medicine in 2014. The award was given to them for their discovery of a certain type of brain cells, so called grid cells. The grid cells alert the body to its location and how to find its way from point A to point B.

Marianne did her PhD with Edvard and May-Britt, playing an essential role in the work that led to the discovery of the grid cells. Marianne was therefore very involved in Norway securing its first Nobel Prize in Medicine.

 

The dark room

Another room in the animal section is completely dark. In the middle of the room, there is an enormous box with various equipment. In the centre of the box, there is a little mouse with an implant on its head.

In this test room, there is an advanced microscope. It uses a laser beam to read the brain activity of the mouse as it alternates between running and standing still on a treadmill.

The researcher Kristian Lensjø is back from a longer study break at the renowned Harvard University and will use some of the methods he has learned.

“I will train the mouse so that it understands that for example vertical lines on a screen mean reward and that horizontal lines give no reward. Then I will look at which brain cells are responsible for this type of learning,” says Kristian.

The students stand behind Kristian and watch the mouse and the computer screen. When the testing begins, they must close the microscope off with a curtain so that the mouse is alone in the dark box. Kristian assures us that the mouse is okay and that he can see what the mouse is doing through an infra-red camera.

“This room and the equipment is so new, we are still experiencing some issues with the tech,” says Marianne. But Christian fixes the problem and suddenly we see something on the computer screen that we have never seen before. It is a look into the mouse’s brain while it runs on the treadmill. This means that the researchers can watch the nerve cells as the mouse looks at vertical and horizontal lines, and detect where the brain activity occurs.

 

Research role models

The students from Ullern know they are lucky to see how cutting-edge neuroscience is done in real life. Marianne and her colleagues are far from nobodies in the research world. Bente Prestegård from Oslo Cancer Cluster and Monica Jenstad, the biology teacher at Ullern who coordinates the work placements, made sure to tell the students beforehand.

“This is a fantastic and unique opportunity for students to get a look into science on a high international level. They can see that the people behind the research are nice and just like any normal people. When seeing good role models, it is easier to picture a future in research for oneself,” says Monica.

“This is a fantastic and unique opportunity for students to get a look into science on a high international level.”

Monica and Marianne have known each other since they were master students together at the University of Tromsø almost twenty years ago.

“I know Marianne very well, both privately and professionally. She is passionate about her research and about dissemination and recruitment. She also works hard to create a positive environment for her research group. Therefore, it was natural to ask Marianne to receive the students and it wasn’t difficult to get her to agree,” says Monica.

Back in the first operating room, Dejana and Malin are still operating on the rats. They will spend the entire day doing this. It takes time when the equipment needs to be found and sterilised, the rats need to be sedated and then operated on as precisely as possibly. It is past noon and time for lunch for Marianne, Kristian and the Ullern students on work placement.

Before I leave them outside Niels Henrik Abels Hus at the Oslo University Campus, I take a picture to remember the extra-ordinary work placement. And not least: to store a picture of the memory in my own brain.

 

Finally, time for lunch! From the left: Emmy Hansteen, Benedicte Berggrav, researcher Marianne Fyhn, Lina Babusiaux, Maren Gjerstad Høgden and researcher Kristian Lensjø. Photo: Elisabeth Kirkeng Andersen.

 

Sign up to OCC newsletter

Photo: Nordic Nanovector

A successful first quarter for Nordic Nanovector

Nordic Nanovector raises NOK 225 million in private placements, begins phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company. These were some of the good news presented in the first quarter 2019 report.

Oslo Cancer Cluster’s member company Nordic Nanovector develops precision medicine against haematological cancers. These are the types of cancers affecting blood, bone marrow and lymph nodes – also known as leukaemia, lymphoma and myeloma. These cancers are notoriously difficult to treat and therefore have a highly unmet medical need.

On the morning of 23 May 2019, the CEO of Nordic Nanovector, Eduardo Bravo, presented some of the successes the company has had during the first quarter of 2019.

“As we advance the clinical development programmes with Betalutin, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner.”

The company’s highlights from the first quarter included raising approximately NOK 225 million in private placements.

They have also extended their clinical trials, known as the PARADIGME study, which address advanced, recurring follicular lymphoma. They now have phase II clinical trials in over 74 sites in 23 countries.

During the first quarter, Nordic Nanovector has also welcomed a new chairman to the Board of Directors – Jan H. Egberts, M.D. He is also the chairperson of the Board of Directors of Oslo Cancer Cluster member Photocure.

Lastly, Dr Mark Wright has been appointed Head of Manufacturing to lead the production of Nordic Nanovector’s therapies. This prepares Nordic Nanovector for future commercialisation and will hopefully lead to more precise treatments successfully reaching cancer patients.

 

Cathrine Wahlström Tellefsen gave a talk to teachers on how programming can be used to teach science subjects in upper secondary schools.

Introducing programming to the curriculum

Programming is not only for computer hackers, it can also help teachers to engage their students in science subjects and inspire start ups to discover new cancer treatments.

 

Almost 60 teachers working in upper secondary schools in Oslo visited Oslo Cancer Cluster Innovation Park and Ullern Upper Secondary School one evening in the end of March. The topic for the event was programming and how to introduce programming to the science subjects in school.

“The government has decided that programming should be implemented in schools, but in that case the teachers first have to know how to program, how to teach programming and, not least, how to make use of programming in a relevant way in their own subjects.”

This was how Cathrine Wahlström Tellefsen opened her lecture. She is the Head of Profag at the University of Oslo, a competence centre for teaching science and technology subjects. For nearly one hour, she talked to the almost 60 teachers who teach Biology, Mathematics, Chemistry, Technology, Science Research Theory and Physics about how to use programming in their teaching.

 

What is KUR? KUR is a collaborative project between Oslo Cancer Cluster, Ullern Upper Secondary School and other schools in Oslo and Akershus. It aims to develop the skills and competence of science teachers. Every six months, KUR arranges a meeting where current topics are discussed.

 

Programming and coding

“Don’t forget that programming is much more than just coding. Computers are changing the rules of the game and we have gained a much larger mathematical toolbox, which gives us the opportunity to analyse large data sets,” Tellefsen explained.

Only a couple of years ago, she wasn’t very interested in programming herself, but after pressures from higher up in her organisation, she gave it a shot. She has since then experienced how programming can be used in her own subject.

“I have been a Physics teacher for many years in an upper secondary school in Akershus, so I know how it is,” she said to calm the audience a little. Her excitement over the opportunities programming provides seemed to rub off on some of the people in the room.

“In biology, for example, programming can be used to teach animal population growth. The students understand more of the logic behind the use of mathematical formulas and how an increase in the carrying capacity of a biological species can change the size of its population dramatically. My experience is that the students start playing around with the numbers really quickly and get a better understanding of the relationships,” said Tellefsen.

When it was time for a little break, many teachers were eager to try out the calculations and programming themselves.

 

Artificial intelligence in cancer treatments

Before the teachers tried programming, Marius Eidsaa from the start up OncoImmunity (a member of Oslo Cancer Cluster) gave a talk. He is a former physicist and uses algorithms, programming and artificial intelligence every day in his work.

“OncoImmunity has developed a method that can find new antigens that other companies can use to develop cancer vaccines,” said Eidsaa.

He quickly explained the principals of immunotherapy, a cancer treatment that activates the patient’s own immune system to recognise and kill cancer cells, which had previously remained hidden from the immune system. The neoantigens play a central role in this process.

“Our product is a computer software program called Immuneprofiler. We use patient data and artificial intelligence in order to get a ranking of the antigens that may be relevant for development of personalised cancer vaccines to the individual patient,” said Eidsaa.

Today, OncoImmunity has almost 20 employees of 10 different nationalities and have become CE-marked as the first company in the world in their field. (You can read more about OncoImmunity in this article that we published on 18 December 2018.)

The introductory talk by Eidsaa about using programming in his start up peaked the audience’s interest and the dedicated teachers eagerly asked many questions.

 

Programming in practice

After a short coffee break, the teachers were ready to try programming themselves. I tried programming in Biology, a session that was led by Monica, a teacher at Ullern Upper Secondary School. She is continuing her education in programming now and it turns out she has become very driven.

“Now you will program protein synthesis,” said Monica. We started brainstorming together about what we needed to find out, which parameters we could use in the formula to get the software Python to find proteins for us.

Since my knowledge in biology is a little rusty, it was a slow process. But when Monica showed us the correct solution, it was surprisingly logical and simple. The key is to stay focused and remember to have a cheat sheet right next to you in case you forget something.

 

Sign up to OCC newsletter

Biobank Norway coordinates Norwegian biobanks with the health industry to ensure that the valuable biosamples are used to develop new, breakthrough treatments.

How will biobanks accelerate cancer research?

Biobanks ­– the powerful tools in cancer research you may have never heard of.

 

Biobank Norway is a national research infrastructure that comprises all public biobanks in Norway and represents one of the world’s largest existing resources within biobanking. They are also a member of Oslo Cancer Cluster, through NTNU, and represent an exciting initiative in the endeavour to develop precision medicine.

 

A biobank is a storage facility that keeps biological samples to be used for medical research. The samples come from population-based or clinical studies.

 

Christian Jonasson, seniorforsker ved NTNU.

Christian Jonasson, seniorforsker ved NTNU.

Christian Jonasson, the Industry Coordinator for Biobank Norway, connects businesses with Norwegian biobanks to accelerate medical research. He said that more biobanks now work with the health industry and benefit from added value in the process.

“It is the health industry that will ultimately bring new therapies to patients.”
Christian Jonasson

Biobank Norway has developed several strategic areas for Norwegian biobanks. They have built automated freezers for secure long-term storage, with advanced robotised systems that can retrieve barcoded biological samples. They have initiated new biobanks, established new IT systems and also developed policies for public-private collaborations. Also, they have contributed to strategic processes that promote increased utilization of Norwegian health data, including the national Health Data Program.

Ultimately, Biobank Norway aims to facilitate collaborations between the global health industry and Norwegian biobanks to accelerate innovation in the life sciences, disease prevention and treatment.

“Biobanks are one of the most important tools in precision medicine.” Christian Jonasson

 

Biosamples may be used for important, life-saving cancer research. For example, to develop new immunotherapies, such as T cell therapy. Photograph by Christopher Olssøn

 

A competitive edge

Norway has been collecting biological samples for the last 30-40 years. For example, one of the world’s largest birth cohort studies, the Mother and Child study (called MoBa) was initiated in 1999. It included 100 000 newborns with mother and father, which totalled over 285 000 participants over a ten-year period. There are numerous other Norwegian health studies, which have involved hundreds of thousands of people, such as the HUNT study and the Tromsø study.

Moreover, the Norwegian Radium Hospital have collected countless valuable samples from cancer patients over the years from both regular clinical care and from clinical research studies. Hospitals across Norway also continually collect and save diagnostic samples, which may be used for medical research at a later stage.

The number of biobanks and the rigorous collection of clinical data in health registers in Norway represent unique assets for medical researchers.

“Norway has a competitive edge on its health data infrastructure.” Christian Jonasson

 

Sharing the data

However, Jonasson also points out that the health registers in Norway are too fragmented. To combat the problem, Biobank Norway are helping the Norwegian Directorate of eHealth to develop a Health Data Program. The digital platform, called the Health Analytics Platform (HAP), will collate copies of relevant data from the various health registers, providing a single point of easy access for researchers.

Biobank Norway also has a long-term vision to collect all biobank data and health data in a common platform. This is a necessary step to unleash a larger national precision medicine initiative. First, they want to organise the data from the four largest population-based cohort studies in one place. In a couple of years, this database would hopefully include 400 000 people, which is a very attractive cohort for medical research.

“We need to attract leading actors from the international health industry and Norwegian start-ups in real collaborations with biobanks.” Christian Jonasson

Important medical research is already being conducted in biobanks across Norway. Jonasson said that there now needs to be a plan to market Norwegian health data and biobanks internationally to spur innovation further.

 

Biosamples are also used for sequencing of the human genome, to develop more precise diagnosis and treatment of cancer.

 

The hidden key

To unlock the potential of biobanks, the biological samples need to be analysed and converted into meaningful data, which can be an expensive and laborious process.

Finland, for example, has begun to collect biological samples from 500 000 individuals. One single database holds all phenotypic data, such as diagnosis and treatment, and all genotypic data, which is the mapping of the human genome.

In the UK, there is the Genomics Project, which has already sequenced the DNA (the coded parts of the human genome) of 100 000 patients. The UK Biobank are aiming to sequence the DNA of half a million brits.

Jonasson hopes that such ambitious initiatives will be imported to Norway to build the biobank infrastructure further and provide meaningful data for medical research. He adds that public-private collaborations will be key to drive and fund such large scale initiatives.

Biobank Norway is currently in the process of extending into its third phase and aims to continue to improve the biobanks, the partner institutions and global research collaborations in the future.

 

  • Do you need help with your research and innovation project using biobanks in Norway?
    E-mail Christian Jonasson.
  • For more information, please visit the official website of BioBank Norway.

 

Sign up to OCC newsletter